High Dose Chemotherapy for Osteogenic Sarcoma

18 cases of osteogenic sarcoma treated with high-dose methotrexate(HDMTX)in our hospitalfrom 1988 to 1993 are reported，which were proven by histopathology except one by X-ray.HDMTX was administrated to all patients at a dose of 0. 5 g/m to 3. 0 g/m with intravenous hy-dration and alkalization. Leucovorin was begun 16 to 18 hours after the start of the methotrexateinfusion at a dose of 12 mg every 6 hours for three days. The 2-year overall survival was 55.600(10/18)for patients with osteogenic sarcoma after receiving postoperative HDMTX chemotherapyand the 5一year overall survival 15. 2%(3/18).The report suggests that the value of adjuvantchemotherapy for osteogenic sarcoma seems well established，HDMTX is one of the effective adj-vant chemotherapy regimens and considerably less toxic when administrated with appropriatedose, hydration, alkalinization，and leucovorin rescue.